产品名称
Anti-Mumps Blend Antibody, fusion protein, clones 570-7A, 570-12G, Chemicon®, from mouse
biological source
mouse
antibody form
purified antibody
antibody product type
primary antibodies
clone
570-12G, monoclonal
570-7A, monoclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
ELISA: suitable
immunofluorescence: suitable
western blot: suitable
isotype
IgG
shipped in
wet ice
Quality Level
Application
Anti-Mumps Blend Antibody, fusion protein, clones 570-7A, 570-12G is an antibody against Mumps Blend for use in ELISA, IF & WB.
EIA at 1:1,000 - 3,000.
Immunofluorescence at 1:1,000 - 3,000.
Final working dilutions must be determined by end user.
Immunofluorescence at 1:1,000 - 3,000.
Final working dilutions must be determined by end user.
Research Category
Infectious Diseases
Infectious Diseases
Research Sub Category
Infectious Diseases - Viral
Infectious Diseases - Viral
Biochem/physiol Actions
Specific for mumps and has shown reactivity to the mumps ENDERS strain.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Immunogen
Epitope: fusion protein
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Physical form
Format: Purified
In 0.02M phosphate buffer, 0.25 NaCl with 0.1% sodium azide.
Preparation Note
Maintain at +2-8°C for up to 12 months.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品？
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
T Vermeire et al.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 25(7), 907-907 (2018-12-07)
Mumps used to affect children between 2 and 15 years old. The mumps-measles-rubella (MMR) vaccine is available, with vaccine coverage rate of about 85% after two vaccine doses. Recently new mumps outbreaks have emerged in highly vaccinated populations; the causes for
Mumps and diabetes.
W P D LOGAN
Monthly bulletin of the Ministry of Health and the Public Health Laboratory Service null
Stephanie Franz et al.
Journal of virology, 91(18) (2017-07-01)
The mumps virus (MuV) small hydrophobic protein (SH) is a type I membrane protein expressed in infected cells. SH has been reported to interfere with innate immunity by inhibiting tumor necrosis factor alpha (TNF-α)-mediated apoptosis and NF-κB activation. To elucidate
J S Ellis et al.
Journal of clinical microbiology, 35(8), 2076-2082 (1997-08-01)
Multiple-target (multiplex) reverse transcription-PCR (RT-PCR) for detection, typing, and subtyping of the hemagglutinin gene of influenza type A (H3N2 and H1N1) and type B viruses was developed and applied prospectively to virological surveillance of influenza in England in the 1995-1996
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持